Abstract:
The present invention relates to a catalyst for preparing 1,3-diphenyl-2-butene type compound represented by the following formula 1. The catalyst has a selective C-C bond forming specificity, and illustrates high transformation ratio to a target compound with high selectivity. Thus, the catalyst of the present invention can be favorably used in a process for preparing 1,3-diphenyl-2-butene type compound.
Abstract:
The present invention relates to a novel hydroxylaminobenzene mutase and a gene coding the same, and a hydroxylaminobenzene mutase catalyzes reaction which rearranges a hydroxyl group in a hydroxylamino compound, thereby being expected to be used for manufacturing pharmaceutical intermediates, various kinds of functional chemical substances, or intermediates.
Abstract:
PURPOSE: An indazole derivative or salt thereof and an insecticidal composition containing the same are provided to eliminate various pests. CONSTITUTION: An indazole derivative is denoted by chemical formula 1. In chemical formula 1, A is N or CH; n and m are individually integer 0-4; V and W are individually hydroxyl, cyano, halogen, C1-6 alkyl, or C1-6 alkoxy; and X, Y, and Z are individually H, hydroxyl, cyano, halogen, C1-6 alkyl, C1-6 alkoxy, , -C(=O)-NH-R1, or -NHC(=O)-O-R2. An insecticidal composition contains the compound of chemical formula 1 as an active ingredient. A method for illuminating mite or insects comprises a step of treating the compound of chemical formula 1 to crops or habitat thereof.
Abstract:
본 발명은 신규의 카르복사미드 유도체, 이의 제조 방법 및 이를 포함하는 살균제 조성물에 관한 것이며, 본 발명에 따른 카르복사미드 유도체는 특히 식물 역병에 대한 살균 효과가 매우 우수하다. 카르복사미드 유도체, 살균제, 농약, 조성물, 토마토, 역병, 살균
Abstract:
PURPOSE: A pharmaceutical composition containing indenone derivative for preventing or treating bone diseases is provided to suppress bone absorption of osteoclast. CONSTITUTION: An indenone derivative is denoted by chemical formula 1. In chemical formula 1, R1 is 5-10 cyclic heteroaryl of C6-C10 aryl, Y is CH, N, N+(-C1-C6alkyl) or N+(-O-). A pharmaceutical composition for preventing and treating bone diseases contains the indenone derivative and physiologically acceptable salt as an active ingredient. The bone diseases is osteoporosis, fracture, periodontal diseases, bone metastatic cancer, or rheumatoid arthritis.
Abstract:
PURPOSE: A benzamide derivative, a manufacturing method thereof, and a prevention and curing pharmaceutical composition containing thereof are provided to prevent the loss of bones, and to prevent the bone diseases including osteoporosis and periodontal disease. CONSTITUTION: A manufacturing method of a benzamide derivative comprises the following steps: reacting a compound marked with chemical formula 2, with a compound marked with chemical formula 3, to obtain a compound marked with chemical formula 4; hydrolyzing the compound marked with the chemical formula 4, to obtain a compound marked with chemical formula 5; and couple-reacting the compound marked with the chemical formula 5, to obtain the benzamide derivative marked with chemical formula 1.
Abstract:
본 발명은 β-아미노알콜 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 TNF-α 매개성 질환의 예방 및 치료용 약학적 조성물에 관한 것으로, 본 발명의 β-아미노알콜 유도체 또는 이의 약학적으로 허용가능한 염은 종양괴사인자-알파(Tumor necrosis factor-α; TNF-α)의 분비를 효과적으로 억제하므로, 본 발명의 β-아미노알콜 유도체를 유효성분으로 함유하는 조성물은 TNF-α 매개성 질환의 예방 및 치료제로 유용하게 사용될 수 있다. [화학식 1]
(상기 식에서, R 1 , R 2 , R 3 , X, Y, m, n 및 은 명세서에서 정의한 바와 같다.) β-아미노알콜 유도체, 종양괴사인자-알파, TNF-α 매개성 질환
Abstract:
본 발명은 광학활성 α-플루오로메틸 프로파길 알콜 유도체의 제조방법에 관한 것으로, 캔디다 안타르크티카( Candida antarctica ) 또는 뮤코 미에헤이( Mucor miehei ) 유래의 리파제 촉매 존재하에, 라세믹 α-플루오로메틸 프로파길 알콜 유도체를 비닐 알카노에이트와 반응시켜 입체선택적으로 에스테르화 반응을 수행함으로써 (-)-형태의 광학활성체와 에스테르 유도체를 얻는 후, 이 에스테르 유도체를 가수분해하여 (+)-형태의 광학활성체를 얻는 것을 특징으로 한다. 이러한 본 발명의 방법에 의하면, 목적하는 광학활성 α-플루오로메틸 프로파길 알콜 유도체를 라세믹 원료화합물로부터 용이하게 얻을 수 있으며, 수득된 광학활성 화합물은 최대 99% ee 이상의 높은 광학순도를 갖는다.
Abstract:
Antifungal azole compounds and a process for preparing the same compounds are provided to improve antifungal activity, especially against fluconazole-resistant Candida albicans, and minimize liver toxicity caused by long-term dosage by enhancing safety of the compounds against the human CytP450 enzyme. The antifungal triazole compounds represented by the formula(1), or pharmaceutically acceptable salts or isomers thereof are provided, wherein R is hydrogen or trifluoromethyl(CF3) group, and X is hydrogen or at least one halogen, C1-4 alkyl group, C1-4 haloalkyl group, C1-4 alkoxy group or dioxymethylene group. The antifungal triazole compounds represented by the formula(1) are prepared by reacting alcohol compounds represented by the formula(2) with styrene compounds represented by the formula(3) in the presence of base in organic solvent.